Welcome to our dedicated page for 111 SEC filings (Ticker: YI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
111, Inc. filings document foreign-issuer current reports furnished on Form 6-K, primarily covering unaudited quarterly and annual financial results for its China healthcare platform. The disclosures report net revenues, gross segment profit, operating expenses, operating cash flow and segment activity tied to the company’s B2B and B2C healthcare businesses.
The filing record also describes the company’s transition toward an asset-light warehouse partnership model, including subsidiary divestitures that shifted certain fulfillment facilities into partner roles. These reports provide formal disclosure of business performance, margin trends, liquidity measures, ADR reporting status and material operating updates furnished to U.S. markets.
111, Inc. (YI) received a non-binding going-private proposal from a consortium comprising co-founders Gang Yu and Junling Liu, Sunny Bay Global Limited and Huadeng Tech BioArray Ventures Ltd to acquire all Class A ordinary shares (including ADSs) they do not beneficially own at US$0.226 per Class A share or US$4.52 per ADS.
The consortium members, who may be deemed a group, collectively beneficially own 72,000,000 Class B and 2,266,328 Class A shares, representing approximately 42.1% of total outstanding share capital and about 91.4% of aggregate voting power based on March 31, 2026 figures plus certain RSUs.
The parties entered into a Consortium Agreement on September 16, 2026 to cooperate exclusively for at least six months on this Proposed Transaction, including agreeing not to make or support competing proposals or trade the issuer’s securities. The proposal is subject to negotiation and execution of definitive agreements, and no party is currently obligated to complete the transaction. If completed, the issuer’s ADSs would be delisted from The Nasdaq Global Market and become eligible for deregistration under Section 12(g)(4) of the Exchange Act.
111, Inc. (YI) reported a sharp revenue contraction and wider losses for the second quarter of 2026 as it continues shifting to an asset-light, platform-focused model. Net revenues were RMB2.30 billion (US$338.995 million), down 28.3% from RMB3.21 billion a year earlier, mainly due to strategic business optimization. B2B net revenue fell 28.7% to RMB2.24 billion, while B2C net revenue declined 7.8% to RMB57.9 million.
Gross segment profit decreased 28.6% year over year to RMB132.3 million. Loss from operations was RMB23.2 million, versus a small profit of RMB0.1 million a year ago, and net loss expanded to RMB31.7 million (1.4% of net revenues) from RMB7.3 million. Non-GAAP net loss was RMB28.9 million, also materially worse than RMB4.4 million in the prior-year quarter. Management highlighted cost actions: fulfillment expenses dropped 29.5% year over year and improved slightly as a percentage of net revenues.
Liquidity weakened. As of June 30, 2026, cash, cash equivalents, restricted cash and short-term investments totaled RMB381.1 million (US$56.2 million), down from RMB611.3 million at December 31, 2025. The company also reported RMB956.7 million included in redeemable non-controlling interests and accrued liabilities owed to investors in 1 Pharmacy Technology; approximately RMB282.2 million has been repaid, and holders of 63.8% of the principal have agreed to restructure redemption over extended periods.
111, Inc. (YI) disclosed that its board received an unsolicited, preliminary, non-binding proposal from a buyer group led by co-founders Dr. Gang Yu and Junling Liu together with Huadeng Tech BioArray Ventures Ltd to take the company private. The proposal contemplates acquiring all outstanding Class A ordinary shares not owned by the group at US$0.226 per Class A Share, or US$4.52 per ADS, in cash in a going-private transaction.
The buyer group states that the proposed price represents a 29.5% premium to the September 15, 2026 ADS closing price and a 20% premium to the 60‑trading‑day average. The co-founders currently hold approximately 1.3% of Class A Shares and 100% of Class B shares, representing about 41.6% of total share capital and 91.3% of voting power. The group proposes to fund the deal entirely with equity (rollover equity plus cash from the sponsor) and indicates the transaction will not be subject to a financing condition. A special committee of independent and disinterested directors is expected to evaluate the proposal, and there is explicit caution that there is no assurance any definitive offer, agreement, or transaction will result.
111, Inc. director Chen Yang Luke reported a mix of RSU grants and share dispositions in Class A ordinary shares. He received awards of 54,759 RSUs on May 11, 2026 and 413,168 RSUs on May 12, 2026, each RSU representing one Class A share.
He also reported open‑market sales of 49,920 shares on June 12, 2026 and 44,000 shares on June 15, 2026 at prices of about $0.23 per share. Footnotes state that additional sales of 1,440 shares on May 26, 2026 and 3,400 shares on May 27, 2026 were made to satisfy tax withholding obligations tied to RSU vesting.
After these transactions, Chen directly holds 495,462 Class A shares. The filing notes that each RSU represents a contingent right to receive one Class A ordinary share, and that as of the Form 4 date the referenced RSUs have fully vested.
111, Inc. director Sun Jian David reported a mix of RSU grants and share sales in Class A ordinary shares. He received grants of 378,737 RSUs on May 11, 2026 and 413,168 RSUs on May 12, 2026, each RSU representing one Class A share.
Between May 26 and June 15, 2026, he sold a total of 397,060 Class A shares at prices between $0.22 and $0.27 per share. Footnotes state that 29,280 and 70,440 of these shares were sold to satisfy tax withholding obligations tied to RSU vesting. After the latest transaction, he holds 413,211 shares directly, and the filing indicates all such RSUs are fully vested as of its date.
111, Inc. director Sun Jian David reported a mix of RSU grants and sales in Class A ordinary shares. He received grants of 378,737 RSUs on May 11, 2026 and 413,168 RSUs on May 12, 2026, each RSU equal to one share. Between May 26 and June 11, 2026, he sold blocks of 29,280, 70,440, 12,000, 115,440 and 111,100 shares at prices around $0.22–$0.27 per share, with the May 26 and May 27 sales specifically used to satisfy tax withholding obligations on vesting RSUs. After these transactions, he directly holds 472,011 RSUs/Class A shares.
111, Inc. director Sun Jian David reported a mix of RSU grants and share sales. On May 11, 2026, he received 378,737 RSUs that vested in full on the grant date. On May 12, 2026, he received a further 413,168 RSUs that vest 25% on each of the first four anniversaries of May 12, 2026, with pro rata vesting if his service ends other than for cause.
Between May 26, 2026 and June 10, 2026, he sold 227,160 Class A ordinary shares tied to RSUs at prices between $0.22 and $0.27 per share. Footnotes state that 29,280 shares and 70,440 shares were sold to satisfy tax withholding obligations on RSU vesting. After these transactions, he directly holds 583,111 RSUs (Class A).
YI submitted a Form 144 notice relating to the proposed sale of 14,867 ADS, where each ADS represents 20 Class A ordinary shares. The filing lists a transaction date of 06/09/2026 and shows an insider, Sun Jian David, with sales of 4,986 ADS on that date and a listed value of $25,901.99.
The filing identifies Citigroup Global Markets as the broker and records the ADS class and related acquisition under a company share incentive plan dated 09/13/2019.
111, Inc. reported weak first quarter 2026 results as it continues shifting to an asset-light, platform-focused model. Net revenue was RMB2.36 billion (US$342.4 million), down 33.1% from the same period last year, mainly due to strategic optimization of its business mix.
Gross segment profit was RMB126.0 million (US$18.3 million), a decline of 35.4%. The company recorded a loss from operations of RMB20.0 million (US$2.9 million), versus a small profit a year ago, and a net loss of RMB26.8 million (US$3.9 million), which also widened on a non-GAAP basis.
Management highlighted growth in marketplace service revenue of 24.7% year over year, modest B2C revenue growth and a 34.6% reduction in fulfillment expenses, reflecting efficiency gains. However, cash, restricted cash and short-term investments fell to RMB396.6 million (US$57.5 million) from RMB611.3 million, and operating cash flow turned negative.
The company also detailed about RMB0.95 billion owed to investors in 1 Pharmacy Technology. It has repaid approximately RMB282.2 million, and investors holding 60.3% of the principal have agreed to restructure and extend redemption terms.
111, Inc. director Luo Jun Justin reported a mix of RSU awards and related share sales. He received grants of 378,737 and 413,168 RSUs, each representing one Class A ordinary share, with the larger grant vesting in stages from May 12, 2026. To satisfy tax withholding obligations tied to RSU vesting, 29,280 Class A shares were sold at $0.27 per share and 70,440 Class A shares were sold at $0.25 per share. After these compensation-related transactions, he holds 710,551 Class A shares directly.